Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 47,698 | 4,936 | N/A | N/A | N/A |
| Marketable Securities | 40,524 | 23,971 | N/A | N/A | N/A |
| TOTAL | $90,405 | $30,624 | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 349 | 442 | N/A | N/A | N/A |
| Other Non-Current Assets | 88 | 2,232 | 0 | 0 | 0 |
| TOTAL | $437 | $2,674 | $N/A | $N/A | $N/A |
| Total Assets | $90,842 | $33,298 | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,971 | 1,658 | 0 | 0 | 0 |
| Accrued Expenses | 4,276 | 2,540 | N/A | N/A | N/A |
| TOTAL | $6,247 | $4,198 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| TOTAL | $160 | $184 | $N/A | $N/A | $N/A |
| Total Liabilities | $6,407 | $4,382 | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 4,394 | N/A | N/A | N/A | N/A |
| Common Shares | 18 | 1 | N/A | N/A | N/A |
| Retained earnings | -96,113 | -54,753 | N/A | N/A | N/A |
| Other shareholders' equity | 4 | 77,796 | 0 | 0 | 0 |
| TOTAL | $84,435 | $28,916 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $90,842 | $33,298 | $0 | $0 | $0 |